Aryl hydrocarbon receptor activation by aminoflavone: New molecular target for renal cancer treatment

  • Authors:
    • Mariana A. Callero
    • Guadalupe V. Suárez
    • Gabriela Luzzani
    • Boris Itkin
    • Binh Nguyen
    • Andrea I. Loaiza-Perez
  • View Affiliations

  • Published online on: April 5, 2012     https://doi.org/10.3892/ijo.2012.1427
  • Pages: 125-134
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Aminoflavone (AF; NSC 686288, AFP464, NSC710464) is a new anticancer drug that has recently entered phase II clinical trials. It has demonstrated antiproliferative effects in MCF-7 human breast cancer cells mediated by the aryl hydrocarbon receptor (AhR). AF also exhibits noteworthy evidence of antitumor activity in vitro and in vivo against neoplastic cells of renal origin. AF treatment of sensitive renal cells, in contrast to resistant cells, promotes the induction of CYP1A1, the covalent binding of AF-reactive intermediates and apoptosis. Based on this evidence, the aim of this study was to evaluate the role of AhR, the main transcriptional regulator of CYP1A1, in the antiproliferative effects of AF in human renal cancer cells. AF-cytoxicity in human renal cell lines and a renal cancer cell strain was assessed by MTS assay in the presence or absence of an Ahr inhibitor. Drug-induced AhR nuclear translocation was evaluated by western blotting of AhR in cytosolic and nuclear fractions and by measuring xenobiotic response element-driven luciferase activity. Apoptosis induced by the drug was evaluated by 4,6-diamidino-2-phenylindole and acridine orange/ethidium bromide staining and by measuring phosphorylated P53 (p-P53) and P21 levels, caspase 3 activation and poly(ADP-ribose) polymerase cleavage. AF inhibited cell growth in a dose-dependent manner in TK-10, Caki-1, SN12-C and A498 human renal cells but not in ACHN cells. The antiproliferative effect of AF was abrogated by pre-incubation of TK-10, Caki-1 and SN12-C cells with the AhR antagonist, α-naphthoflavone. AF treatment also induced apoptosis in TK-10, Caki-1 and SN12-C cells, which was not observed in ACHN cells. AF induced time-dependent AhR nuclear translocation and AhR transcriptional activity in sensitive renal cancer cell lines. A renal cell strain derived from a human papillary tumor also showed sensitivity to AF, as well as AhR pathway activation and drug-induced apoptosis. AhR translocation could be included as a marker of sensitivity to AF in sensitive renal tumor cells of different histological origin, in ongoing phase II clinical trials.

Related Articles

Journal Cover

July 2012
Volume 41 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Callero MA, Suárez GV, Luzzani G, Itkin B, Nguyen B and Loaiza-Perez AI: Aryl hydrocarbon receptor activation by aminoflavone: New molecular target for renal cancer treatment. Int J Oncol 41: 125-134, 2012
APA
Callero, M.A., Suárez, G.V., Luzzani, G., Itkin, B., Nguyen, B., & Loaiza-Perez, A.I. (2012). Aryl hydrocarbon receptor activation by aminoflavone: New molecular target for renal cancer treatment. International Journal of Oncology, 41, 125-134. https://doi.org/10.3892/ijo.2012.1427
MLA
Callero, M. A., Suárez, G. V., Luzzani, G., Itkin, B., Nguyen, B., Loaiza-Perez, A. I."Aryl hydrocarbon receptor activation by aminoflavone: New molecular target for renal cancer treatment". International Journal of Oncology 41.1 (2012): 125-134.
Chicago
Callero, M. A., Suárez, G. V., Luzzani, G., Itkin, B., Nguyen, B., Loaiza-Perez, A. I."Aryl hydrocarbon receptor activation by aminoflavone: New molecular target for renal cancer treatment". International Journal of Oncology 41, no. 1 (2012): 125-134. https://doi.org/10.3892/ijo.2012.1427